Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P59046

UPID:
NAL12_HUMAN

ALTERNATIVE NAMES:
Monarch-1; PYRIN-containing APAF1-like protein 7; Regulated by nitric oxide

ALTERNATIVE UPACC:
P59046; A8MTQ2; B3KTE7; Q8NEU4; Q9BY26

BACKGROUND:
The protein NACHT, LRR, and PYD domains-containing protein 12, with aliases such as Monarch-1 and Regulated by nitric oxide, is a key inhibitor of inflammation. It functions by suppressing NF-kappa-B and ERK pathways, targeting NOD2 for degradation, and adjusting immune responses to bacterial and viral challenges.

THERAPEUTIC SIGNIFICANCE:
Given its association with Familial cold autoinflammatory syndrome 2, exploring the functions of this protein offers promising avenues for developing targeted treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.